The Valence Group adviseert Eurazeo over aankoop Novacap van Ardian
LONDEN–(BUSINESS WIRE)– The Valence Group heeft Eurazeo geadviseerd over de overname van Novacap, een internationale speler in de farmaceutische en chemische industrie, voor een bedrijfswaarde van 654 miljoen euro (746 miljoen dollar), plus 30 miljoen euro (34 miljoen dollar) aan zogeheten earnout. Na de aankoop wordt Eurazeo de grootaandeelhouder van Novacap, met 67 procent van het aandelenkapitaal in het bezit. Daarnaast zijn Mérieux Développement (9%), Ardian (18%) en het bestuur (6%) aandeelhouder.
Novacap is een internationale groep die actieve farmaceutische ingrediënten (Active Pharmaceutical Ingredients, API’s) en essentiële chemicaliën voor alledaagse toepassingen produceert en distribueert. Bestemmingen van deze ingrediënten zijn bijvoorbeeld aspirine, paracetamol, andere API’s, salicylzuur, 4-aminofenol, soda, fenol, zuurstofrijke solvents en ijzer(III)chloride. Novacap kan bogen op leidende posities in groeiende markten, zoals de farmacie en de gezondheidszorg, cosmetica en parfumerie, voedsel en voer, huishouden en het milieu. De groep is sectorleider in uiteenlopende producttypes (zoals de nummer 1-positie in aspirine en salicylzuur wereldwijde, en de nummer 2-positie in paracetamol en natriumbicarbonaat in Europa). Novacap benut de kansen van een solide Europees platform dat wordt aangevuld door zijn verankerde aanwezigheid in Azië en groeiend afzetgebied in Noord-Amerika.
The Valence Group Advises Eurazeo on Its Acquisition of Novacap from Ardian |
|||||
|
LONDON–(BUSINESS WIRE)– The Valence Group has advised Eurazeo on its acquisition of Novacap, a global participant in the pharmaceutical and chemicals industry, for an enterprise value of €654m ($746m 1), plus up to a €30m ($34m 1) earn-out. Following the acquisition, Eurazeo will become the majority shareholder of Novacap with 67% of the equity capital, alongside Mérieux Développement (9%), Ardian (18%) and management (6%). Pending the approval of regulatory authorities, the transaction should be completed by the summer. Novacap is an international group that produces and distributes Active Pharmaceutical Ingredients (APIs) and essential chemicals products that are used in everyday applications such as aspirin, paracetamol, other APIs, salicylic acid, para-aminophenol, soda ash, sodium bicarbonate, phenol, oxygenated solvents and ferric chloride. Novacap enjoys leading positions in growing end-markets, such as pharmaceutical & healthcare, cosmetics & fragrances, food & feed, home care and environment. The group is an industry leader across a wide range of products (e.g. No.1 in aspirin and salicylic acid globally, No.2 in paracetamol and sodium bicarbonate in Europe). It benefits from a solid European platform complemented by a well-established presence in Asia and an increasing footprint in North America. With over 750 customers across more than 80 countries, Novacap generated revenue of €634m ($723m 1) in 2015. Headquartered in Lyon (France), Novacap employs around 1,600 people across 14 industrial facilities worldwide and has a global commercial network. The company has flourished in recent years, with significant EBITDA growth from €45.6m in 2010 (9.7% margin) to €91.5m ($104m 1) pro forma in 2015 (14.4% margin). Ardian, formerly known as Axa Private Equity, has owned the business since 2011. About Eurazeo Eurazeo is one of the largest European listed investment companies with approximately €5 billion in net assets. Its solid institutional and family shareholder base, robust financial structure and flexible investment horizon enable Eurazeo to support its companies over the long term. Novacap represents Eurazeo’s first investment in the pharmaceuticals and chemicals industries. Eurazeo is listed on Euronext Paris (EURA.PA). About The Valence Group The Valence Group is a specialist investment bank offering M&A advisory services exclusively to companies and investors in the chemicals, materials and related sectors. The Valence Group team includes a unique combination of professionals with backgrounds in investment banking and strategic consulting within the chemicals and materials industries, all focused exclusively on providing M&A advisory services to the chemicals and materials sector. The firm’s offices are located in New York and London.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160411006193/en/ Contacts The Valence Group |
|||||